Dixogin in cardiac patient

Reading File

Finding Sources

Searching PubMed

digoxin heart failure atrial fibrillation

Reading File

Finding Sources

I now have all the information needed for a comprehensive answer on Digoxin in cardiac patients.

Digoxin in Cardiac Patients

Overview

Digoxin (the drug you are referring to as "Dixogin") is a cardiac glycoside derived from the Digitalis (foxglove) plant, first described by William Withering in 1775. It is one of the oldest drugs in cardiovascular medicine and remains in use today for specific indications, though its role has narrowed considerably with modern therapies.

Braunwald's Heart Disease, p. 470
Lippincott Pharmacology, p. 373

Mechanism of Action

Digoxin works through three main mechanisms:

1. Na⁺/K⁺-ATPase Inhibition (Positive Inotropy)

Digoxin inhibits the Na⁺/K⁺-ATPase pump on cardiac myocytes. This raises intracellular Na⁺, which in turn reduces Ca²⁺ extrusion via the Na⁺/Ca²⁺ exchanger, raising intracellular Ca²⁺ - leading to increased contractility.

2. Enhanced Vagal Tone (Rate Control)

Digoxin sensitizes Na⁺/K⁺-ATPase in vagal afferent nerves, increasing vagal tone. This slows the sinus node discharge rate and prolongs AV nodal refractoriness - making it useful for rate control in atrial fibrillation (AF).

3. Neurohormonal Inhibition

At low doses, digoxin inhibits sympathetic activation with minimal effect on contractility. This is the primary rationale for its use in HFrEF (Heart Failure with Reduced Ejection Fraction).

Lippincott Pharmacology, p. 373

Indications in Cardiac Patients

Indication	Details
Heart Failure with Reduced EF (HFrEF)	Added for symptomatic benefit only after optimal therapy (ACE-I/ARB/ARNI + beta-blocker + MRA + SGLT2i). Target serum level: 0.5-0.9 ng/mL
Atrial Fibrillation - rate control	Used orally for chronic AF; IV for acute ventricular rate control. Controls rate at rest in 40-60% of cases. NOT effective as sole agent during exercise
Pediatric arrhythmias	Wider use in pediatrics than adults

Digoxin does NOT reduce mortality in HF. It reduces hospitalizations and improves symptoms but is not a survival drug. It does not convert AF to sinus rhythm and is inferior to adenosine, verapamil, or beta-blockers for SVT termination.

Braunwald's Heart Disease, pp. 1874-1876, 2791

Dosing

Setting	Dose
Chronic oral maintenance	0.125-0.25 mg/day (most patients: 0.125 mg/day)
Acute loading (oral/IV)	0.5-1.0 mg in divided doses
Elderly / renal impairment / low lean body mass	0.125 mg/day (serum level <1.0 ng/mL)
Renal dialysis patients	0.125 mg every other day
Target serum level (HFrEF)	0.5-0.9 ng/mL
Target serum level (general)	<1.0 ng/mL

Dosage is based on lean body weight. Digoxin has a long half-life of 30-40 hours and is primarily eliminated by the kidneys unchanged - requiring dose adjustment in renal dysfunction.

Lippincott Pharmacology, p. 374; Braunwald's Heart Disease, p. 2789

Pharmacokinetics

Oral and IV formulations available
Large volume of distribution (accumulates in muscle)
Half-life: 30-40 hours
Elimination: Renal (intact drug)
IV digoxin shows electrophysiologic effect within minutes, with peak effect occurring later

Adverse Effects & Toxicity

Digoxin has a very narrow therapeutic index - a small difference separates therapeutic and toxic doses.

Early / GI Symptoms (often first sign)

Anorexia, nausea, vomiting
Headache, malaise, weakness, dizziness, delirium

Visual Symptoms

Blurred vision, yellowish/green tinted vision (xanthopsia), halo vision, altered color perception

Cardiac Arrhythmias (serious)

Bradycardias (vagal): sinus bradycardia/arrest, AV block (1st, 2nd, 3rd degree)
Tachyarrhythmias (DAD-triggered): junctional tachycardia, fascicular VT, bidirectional VT (classic sign of toxicity), PVCs
Characteristic ECG change: "Salvador Dali moustache" - reverse tick ST depression (not toxicity, just digitalis effect)

Factors that Increase Sensitivity to Toxicity

Hypokalemia (most important - shares binding site with K⁺)
Hypomagnesemia
Renal impairment
Advanced age
Hypothyroidism
Chronic lung disease
Amyloidosis
Braunwald's Heart Disease, p. 2793; Lippincott Pharmacology, p. 374

Drug Interactions (Major)

Drug	Effect
Amiodarone	Doubles digoxin level - reduce digoxin dose by 50%
Quinidine	Raises digoxin level significantly
Verapamil	Raises digoxin level
Flecainide	Raises digoxin level
Erythromycin / Tetracycline	Raise digoxin level (alter gut flora, increase absorption)
Diuretics (thiazide/loop)	Cause hypokalemia → precipitate toxicity
Cyclosporine	Raises digoxin level (P-glycoprotein competition)

These interactions are common and clinically significant - always check when prescribing concomitantly.

The Washington Manual of Medical Therapeutics; Swanson's Family Medicine Review

Treatment of Digoxin Toxicity

Intervention	Use
Withdraw digoxin	First step for most bradycardias
Correct electrolytes (K⁺, Mg²⁺)	Essential - correct hypokalemia immediately
Atropine / temporary pacing	For symptomatic bradycardia/AV block
Phenytoin	Atrial tachyarrhythmias
Lidocaine	Infranodal (ventricular) tachycardias
Digoxin-specific antibody fragments (Digoxin-Fab)	Life-threatening arrhythmias; also effective in cardiac arrest (50% survival reported) - cross-reacts with other cardiac glycosides
DC cardioversion	Avoid if possible - risk of precipitating VT/VF; use only when absolutely necessary

Braunwald's Heart Disease, p. 2795; Tintinalli's Emergency Medicine

Key Points to Remember

Digoxin does NOT improve survival in HF - it reduces symptoms and hospitalizations only
It is a last-line agent in HFrEF, added only after quadruple therapy (ACEi/ARNI + beta-blocker + MRA + SGLT2i)
Rate control with digoxin in AF is good at rest, poor on exertion - rarely used alone for this purpose
Target serum level in HFrEF is lower (0.5-0.9 ng/mL) to harness neurohormonal benefit with minimal inotropy
Hypokalemia is the most dangerous precipitant of digoxin toxicity
Use is generally discouraged in adults due to narrow therapeutic window; use has significantly declined with modern alternatives

Recent evidence note: A 2025 Expert Consensus on Digoxin Toxicity (PMID 39265879, Am J Med) reaffirms the diagnostic and management principles summarized above, underscoring that digoxin-Fab fragments remain the treatment of choice for life-threatening toxicity.

This is a shared conversation. Sign in to Orris to start your own chat.